|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies.
|
15310462 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the fundamental role of the corticotropin-releasing hormone (CRH) system in anxiety, stress-associated pathologies, and mood disorders, we describe genetic modifications of the genes that encode proteins integral to the CRH/CRH receptor system with particular emphasis on conditional gene-targeting strategies.
|
14755129 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Although negative affect mediated in part by corticotropin-releasing factor (CRF) is a strong motivator for alcohol consumption in adults, comparisons of alcohol withdrawal in adolescents and adults generally have not included CRF-related measures such as anxiety.
|
30566247 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin releasing factor (CRF) receptors belong to the secretin family of G proteincoupled receptors (GPCRs) and are responsible for initiating endocrine stress responses and mediating anxiety related behaviors upon activation via stressors.
|
28103782 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
We investigated the effect of tetrahydroprogesterone on corticotropin-releasing hormone-induced anxiety, the basal and methoxamine-stimulated release of corticotropin-releasing hormone from hypothalamic organ explants in vitro, and adrenalectomy-induced up-regulation of the gene expression of corticotropin-releasing hormone in the hypothalamic paraventricular nucleus in rats.
|
7816204 |
1994 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety.
|
12424556 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin releasing factor (CRF) is a key component of stress responsivity, modulating related behaviors including anxiety and reward.
|
30266597 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing factor binds with high affinity to CRF receptor 1 (CRFR1) and is implicated in stress-related mood disorders such as anxiety and depression.
|
30499109 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Chronic CRH depletion from GABAergic, long-range projection neurons in the extended amygdala reduces dopamine release and increases anxiety.
|
29786085 |
2018 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
VacA causes anorexia and anxiety through the intracellular PLC-PKC pathway, migrates across the blood-brain barrier, and activates the Ucn1-CRF receptor axis.
|
30979915 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
|
16733617 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Maternal behavior and anxiety are potently modulated by the brain corticotropin-releasing factor (CRF) system postpartum.
|
29477300 |
2018 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Pexacerfont is a corticotropin-releasing factor subtype 1 receptor antagonist that was developed for the treatment of anxiety- and stress-related disorders.
|
30760067 |
2020 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
These results suggest that the onset of r/hCRF and rUcn actions related to behavioral responses to anxiety is likely to depend on brain peptide-specific mechanisms including binding properties to CRF-receptors, differential distribution to specific functional brain sites and the distribution and effectiveness of binding-protein interactions.
|
11875628 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Further exploration of mechanisms by which endogenous OT system is modulated by CRF peptide family is needed to better understand the role of these neuropeptides in the regulation of anxiety and the stress response.
|
29618970 |
2018 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Taken with the evidence for hypersecretion of CRF in patients with depression and anxiety-related disorders, our findings lead to the intriguing hypothesis that interaction between CRF and 5-HT, especially in the ventral hippocampus, plays a role in the etiology of affective and anxiety disorders.
|
14575894 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We focus our efforts on describing CRF modulation of biogenic amine neuron populations that have widespread projections to the forebrain to modulate behaviors, including alcohol and drug intake, stress reactivity, and anxiety.
|
30217435 |
2018 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This paper explores the interactions of glucocorticoids and CRH in the presentation of anxiety and depressive disorders in an effort to better describe their differing roles in each of these clinical presentations.
|
28119322 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Genetic modifications of the CRH system by conventional and conditional gene targeting strategies in the mouse allowed us to study the endogenous mechanisms underlying HPA system regulation and CRH-related neuronal circuitries involved in pathways mediating anxiety and stress-related behaviour.
|
15771006 |
2005 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings identify a CRF<sup>CeA</sup>→CRF<sup>dlBST</sup> circuit for generating anxiety-like behavior and provide mechanistic support for recent human and primate data suggesting that the CeA and BST act together to generate states of anxiety.<b>SIGNIFICANCE STATEMENT</b> Anxiety is a negative emotional state critical to survival, but persistent, exaggerated apprehension causes substantial morbidity.
|
30530860 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
The Y1 receptor antagonist blocked the anxiolytic-like effect of neuropeptide Y, while the Y2 receptor antagonist was ineffective.We conclude that neuropeptide Y in the dorsocaudal lateral septum may act as an endogenous anxiolytic and antagonize corticotropin-releasing hormone (stress)-induced anxiety.
|
11440811 |
2001 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
A concatenation of findings from preclinical and clinical studies support a preeminent function for the corticotropin-releasing factor (CRF) system in mediating the physiological response to external stressors and in the pathophysiology of anxiety and depression.
|
20010888 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The corticotropin releasing hormone (CRH) system has been implicated in a variety of anxiety and mood-based symptoms and disorders.
|
24123648 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CRF elicited a wide range of behaviors, which fell into three broad categories: anxiety-like, depressive-like, and externally oriented.
|
12438692 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration.
|
17293045 |
2007 |